Younghoon Kim and Eleftherios Mylonakis\*

*Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114*

Received 25 January 2011/Accepted 4 April 2011

**Although bacterial-fungal interactions shape microbial virulence during polymicrobial infections, only a limited number of studies have evaluated this interaction on a genetic level. We report here that one interaction is mediated by** *sopB***, an effector of a type III secretion system (TTSS) of** *Salmonella enterica* **serovar Typhimurium. In these studies, we screened 10 TTSS effector-related mutants and determined their role in the killing of** *C. albicans* **filaments** *in vitro* **during coinfection in planktonic environments. We found that deleting the** *sopB* **gene (which encodes inositol phosphatase) was associated with a significant decrease in** *C. albicans* **killing at 25°C after 5 days, similar to that caused by the deletion of** *sipB* **(which encodes TTSS translocation machinery components). The** *sopB* **deletion dramatically influenced the killing of** *C. albicans* **filaments. It was associated with repressed filamentation in the** *Caenorhabditis elegans* **model of** *C. albicans***-***S.* **Typhimurium coinfection, as well as with biofilm formation by** *C. albicans***. We confirmed that SopB translocated to fungal filaments through SipB during coinfection. Using quantitative real-time PCR assays, we found that the** *Candida* **supernatant upregulated the** *S.* **Typhimurium genes associated with** *C. albicans* **killing (***sopB* **and** *sipB***). Interestingly, the s***opB* **effector negatively regulated the transcription of** *CDC42***, which is involved in fungal viability. Taken together, these results indicate that specific TTSS effectors, including SopB, play a critical role in bacterialfungal interactions and are important to** *S.* **Typhimurium in order to selectively compete with fungal pathogens. These findings highlight a new role for TTSS of** *S.* **Typhimurium in the intestinal tract and may further explain the evolution and maintenance of these traits.**

Microbial survival is based on diverse bacterial-bacterial, fungal-fungal, and bacterial-fungal interactions. These interactions are ubiquitous in nature, as well as in clinical environments, but very little is known about the genetic mechanism(s) associated with these interactions (51). Most of the previous studies have focused on *Candida albicans*, the opportunistic fungal pathogen that can exist as both yeast and filamentous cells according to its growing circumstances and conditions (59). *C. albicans* is the most common pathogenic fungus and may cause mucosal and systemic infections in immunosuppressed and immunocompetent hosts. The morphological transition from a yeast to a filamentous cell is critical for *C. albicans* pathogenesis (34, 55). Interestingly, the ability of *C. albicans* to develop filaments is also impacted by the presence of bacterial pathogens (8), and this association was extensively described during the interaction between *C. albicans* and various pathogenic bacteria, including *Streptococcus gordonii* (5), *Staphylococcus epidermidis* (2), *Pseudomonas aeruginosa* (25), *Burkholderia cenocepacia* (8), and *Acinetobacter baumannii* (52). However, limited work has been done on the interaction of *C. albicans* with intestinal bacterial pathogens. These studies are particularly important because in the human intestinal tract there exists a remarkable microbial community that includes *C. albicans* in essentially all humans (28, 51, 54).

\* Corresponding author. Mailing address: Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114. Phone: (617) 726-3812. Fax: (617) 726-7416. E-mail: emylonakis@partners.org.<br>
<sup>v</sup> Published ahead of print on 15 April 2011.

*Salmonella enterica* serovar Typhimurium is one of the most common food-borne pathogens and can cause intestinal inflammation leading to diarrheal diseases in humans and animals (58). The type III secretion systems (TTSS) encoded by *Salmonella* pathogenicity island 1 (SPI-1) and SPI-2 on the bacterial chromosome are important virulence factors for *Salmonella* pathogenesis (74). Simply put, TTSS represents a molecular syringe allowing the bacteria to deliver effector proteins directly into the host cell cytosol (35, 74). To date, more than 30 SPI-1- and SPI-2-regulated effectors in *Salmonella* are known to use these systems to translocate these proteins into the host cell cytoplasm (37). Despite the importance of the TTSS in pathogenesis, the recognition and targeting of TTSS effectors remains poorly understood (17).

In previous work we found that the human intestinal pathogen *S.* Typhimurium significantly influenced the survival of *C. albicans* filaments (67). We found in the present study that the *sopB* effector is essential for competing with *C. albicans* filaments, and we show that *S.* Typhimurium influences the survival and filamentation of *C. albicans* in a *Caenorhabditis elegans* model and biofilm formation through the TTSS *sopB* effector. Moreover, the *sopB* effector can repress *TEC1* (which encodes a transcription factor for filamentation and biofilm formation), *HWP1* and *ALS3* (which encode filament specific cell wall proteins), and *CDC42* (which encodes a Rho-type GTPase that is related to viability) in *C. albicans*.

### **MATERIALS AND METHODS**

**Fungal and bacterial strains, plasmids, and growth conditions.** The strains and plasmids used in the present study are listed in Table 1. *C. albicans* and *S.*

TABLE 1. Strains and plasmids used in this study

Strain or plasmid	Genotype and/or relevant characteristics <sup>a</sup>	
Bacterial strains		
<b>HB101</b>	Nonpathogenic E. coli; normal food source for C. elegans	11
14028	S. Typhimurium wild-type	$ATCC^b$
$\triangle$ sop $B$	$\triangle$ sopB $\Omega$ Km <sup>r</sup> ; Salmonella outer protein; homologue to ipgD of Shigella; regulated by SPI-1	58
$\Delta$ sop $D$	$\Delta$ sopD $\Omega$ Km <sup>r</sup> ; secreted protein in the Sop family; transferred to eukaryotic cells; regulated by SPI-1	58
$\Delta$ sop $E2$	$\Delta$ sopE2 $\Omega$ Km <sup>r</sup> ; type III secreted protein effector; regulated by SPI-1	58
$\Delta$ sip $B$	$\Delta sipB$ $\Omega$ Km <sup>r</sup> ; cell invasion protein; regulated by SPI-1	58
$\Delta invA$	$\Delta invA$ $\Omega$ Km <sup>r</sup> ; invasion protein; regulated by SPI-1	58
$\Delta$ ssa $E$	$\Delta s$ saE $\Omega$ Km <sup>r</sup> ; secretion system effector; regulated by SPI-2	58
$\triangle$ sse $B$	$\triangle$ sseB $\Omega$ Km <sup>r</sup> ; secretion system effector; regulated by SPI-2	58
$\triangle$ sseJ	$\Delta$ sseJ $\Omega$ Km <sup>r</sup> ; Salmonella translocated effector; regulated by SPI-2	58
$\Delta adrA$	$\Delta adrA \Omega$ Km <sup>r</sup> ; putative diguanylate cyclase/phosphodiesterase domain 1	58
$\Delta l$ ux $S$	$\Delta luxS$ $\Omega$ Km <sup>r</sup> ; quorum-sensing protein, produces autoinducer signaling molecules	58
$\Delta phoP$	$\Delta phoP$ $\Omega$ Km <sup>r</sup> ; response regulator in two-component regulatory system	58
$\Delta$ ssr $A$	$\Delta$ ssrA $\Omega$ Km <sup>r</sup> ; two-component regulatory system	58
14028-GFP	14028 wild type containing pCM18	This study
$\Delta$ sopB-GFP	$\Delta$ sopB containing pCM18	This study
14028/SopB	14028 wild type containing pSB2908	This study
$\Delta$ sipB/SopB	$\Delta$ sipB containing pSB2908	This study
$\Delta$ sopB/SopB	$\Delta$ <i>sopB</i> containing pSB2908	This study
Candida strains		
<b>DAY185</b>	$ura3\Delta::\lambda imm434/ura3\Delta::\lambda imm434$ his1::hisG/HIS1::his1::hisG arg4::hisG/URA3::ARG4::arg4::hisG	13
$\Delta t$ up $1$	$ura3\Delta$ :: $\lambda$ imm434/ $ura3\Delta$ :: $\lambda$ imm434 his1::hisG/tup1::hisG-URA3-hisG	10
$\Delta$ suv $\Im$	ura3 $\Delta$ ::\imm434/ura3 $\Delta$ ::\imm434 suv3::Tn7-URA3/suv3::Tn7-UAU1 his1::hisG/his1::hisG arg4::hisG/arg4::hisG	55
SC5314	Clinical isolate	19
$\Delta cph1/\Delta e$ fg1	$ura3\Delta::\lambda imm434/ura3\Delta::\lambda imm434 cph1\Delta::hisG/cph1\Delta::hisG/ef1\Delta::hisG/ef1\Delta::hisG-URA3-hisG$	34
$SSY50-B$	ura3 $\Delta$ :: $\lambda$ imm434/tet-NRG1/URA3	59
Plasmids		
pCM18	$Emr$ ; pTRKL2-P <sub>CP25</sub> -RBSII- <i>gfpmut3</i> ; broad host	21
pSB2908	Am <sup>r</sup> ; pBAD24 $P_{190}$ ::FLAG-tagged SopB <sup>+</sup> ; arabinose inducible	50

*<sup>a</sup>* Am<sup>r</sup> , Em<sup>r</sup> , and Km<sup>r</sup> represent ampicillin, erythromycin, and kanamycin resistance, respectively. *<sup>b</sup>* ATCC, American Type Culture Collection.

Typhimurium strains were routinely cultured in yeast-peptone-dextrose (YPD) at 30°C and Luria-Bertani (LB) medium (Difco, Detroit, MI) at 37°C, respectively. When necessary, kanamycin (45  $\mu$ g/ml), ampicillin (100  $\mu$ g/ml), and erythromycin (300  $\mu$ g/ml) were used for selective culture of mutants.

**Nematode strains.** *C. elegans glp-4*(*bn2*);*sek-1*(*km4*) strain was used for all experiments as described previously (11, 43). The *C. elegans glp-4* mutant animals are suited for liquid assay experiments since worms are unable to produce progeny at 25°C; however, sterile animals have enhanced life span compared to wild-type animals (41). *C. elegans sek-1* encodes a conserved mitogen-activated protein kinase kinase involved in innate immunity (29), expediting the time of experiments. Worms were cultured and maintained on *Escherichia coli* HB101 by using standard procedures (11).

*In vitro* **coinfection assay under planktonic environments.** *In vitro* coculture assays were performed in 2 ml of LB broth and incubated in a roller drum at 25°C for 5 days (52). A starting inoculum of ca. 10<sup>6</sup> CFU/ml of *S.* Typhimurium strain 14028 wild type or its isogenic mutants (58) (Table 1) and ca.  $5 \times 10^5$  cells/ml of *C. albicans* DAY185 were used for all experiments. To quantify the viability of *C. albicans* in coinfection conditions, we used CFU analysis as previously described (22, 25, 67). YPD agar plates containing kanamycin (45  $\mu$ g/ml), ampicillin (100  $\mu$ g/ml), and streptomycin (100  $\mu$ g/ml) were used to select for *C. albicans* strains. The CFU were determined by diluting cells by  $10^0$  to  $10^7$  via 10-fold serial dilution steps in  $0.85\%$  NaCl solution that was applied as 10- $\mu$ l drops on agar plates (14). The YPD agar plates were incubated at 30°C for 48 h. Two independent cultures were used for each strain.

*In vitro* **coinfection assay for filament specific killing.** In order to monitor the killing and inhibition of *C. albicans* filaments via the *sopB* effector, we evaluated *C. albicans* filaments from *C. albicans tup1* and *C. albicans* SSY50-B. *C. albicans*  $\Delta t \mu pI$  is a strain that constitutively produces filaments at 25°C, while the  $\Delta s \mu v3$ mutant produces no filaments under the same conditions (10, 55). In addition, we studied the genetically engineered strain *C. albicans* SSY50-B (tetracyclineregulatable *tet*-*NRG1*) that constitutively forms filaments in the presence of 20  $\mu$ g of doxycycline (DOX)/ml at 37°C but does not produce filaments in the absence of DOX (59). Using these strains, we evaluated the viability of *C. albicans* filaments infected with *S.* Typhimurium strains by using the XTT [2,3 *bis*-(2-methoxy-4-nitro-5-sulfophenyl)-2*H*-tetrazolium-5-carboxanilide] assay as described earlier (38) with slight modifications. More specifically, *C. albicans tup1* and *suv3* were cultured at 25°C for 48 h in order to produce filaments and yeast cells, respectively. In addition, *C. albicans* SSY50-B was grown at 37°C for 24 h with or without 20  $\mu$ g of DOX/ml to facilitate the formation of filaments and yeast-type cells, respectively. Filaments and normal yeast cells were washed three times with phosphate-buffered saline (PBS) and incubated with 10<sup>6</sup> CFU of *S*. Typhimurium/ml in LB medium for 24 h. After incubation, the *C. albicans* filaments were recovered by centrifugation at 5,000 rpm for 3 min, washed three times by PBS, and then the XTT-menadione solution, consisting 10 ml of XTT (0.5 mg/ml in PBS) and 1  $\mu$ l of menadione (10 mM menadione in acetone) was added. After incubation for 2 h at  $37^{\circ}$ C and centrifugation, 80  $\mu$ l of the XTTmenadione supernatants was transferred to the wells of a 96-well microtiter plate, and measured by using a microtiter plate reader (Molecular Devices, Sunnyvale, CA) at 490 nm. All results were normalized based on the *E. coli* HB101 control.

*C. elegans* **coinfection assay for filamentation.** The *C. elegans* coinfection assays for *C. albicans* filamentation were performed as previously described (67). In brief, synchronized, young adult nematodes were preinfected for 4 h on lawns of *C. albicans* DAY185 and then transferred into wells of a six-well microtiter dish (40 worms per well), followed by three washes with M9 medium. Each well contained 2 ml of liquid assay medium (20% brain heart infusion and 80% M9). *S*. Typhimurium strains were inoculated at the concentration of ca. 10<sup>6</sup> CFU/ml before the addition of the *C. albicans*-infected worms. The plates were then incubated at 25°C and examined at 24-h intervals for 6 days for viability and the formation of penetrative filaments by using a Nikon SMZ645 dissecting microscope. In addition, to evaluate whether *Salmonella* strains influence filament elongation of *C. albicans* in *C. elegans*, worms with initial filamentation (worms

with filaments after 1 day) were moved to new wells of 96-well plates (Corning no. 3882), including *S.* Typhimurium strains expressing green fluorescent protein (GFP) (Table 1; ca. 10<sup>6</sup> CFU/ml) in liquid assay medium and then incubated at 25°C for an additional 5 days. The qualitative observation of *C. albicans* filamentation and elongation in *C. elegans* was performed by using a Discovery-1 microscope (Molecular Devices, Sunnyvale, CA) using a fluorescein isothiocyanate (FITC) filter set or with bright-field transmitted light.

*S.* **Typhimurium attachment to** *C. albicans* **filaments.** To evaluate the filamentation *in vitro*, *C. albicans* SSY50-B (59) organisms were inoculated into YPD with 20 µg of DOX/ml in 96-well plates (Corning, Inc., Corning, NY; no. 3882) and incubated for 8 h at 37°C with shaking at 150 rpm. After incubation, the wells were washed five times with PBS, and ca. 10<sup>6</sup> CFU/ml of *Salmonella* strains expressing GFP in LB containing erythromycin  $(300 \mu g/ml)$  were added, followed by incubation for 15 h at 37°C. After six washings with PBS to remove unattached *Salmonella* strains, GFP-expressing *Salmonella* strains on *C. albicans* filaments were observed by using a Discovery-1 microscope under FITC and bright-field light. In addition, *S.* Typhimurium cells attached to *C. albicans* filaments were counted by using the CFU assay, following recovery of *C. albicans* filaments from 96-well plates using vigorous pipetting. LB agar plates containing fluconazole (32 µg/ml) were used to select for *S*. Typhimurium. Plates were incubated at 37°C for 24 h.

**Silicone pad biofilm assay.** The effect of *S.* Typhimurium on *C. albicans* biofilm growth was evaluated by using a polymicrobial silicone pad assay as described previously (52). Spider medium (32) was used as the medium for *C. albicans* biofilm development. The quantitative biofilm mass was calculated by subtracting the original weight of the silicone pad from its postincubation (60 h) weight and adjusting for the weight of control silicone pads exposed without fungal cells.

**Monitoring of SopB in** *C. albicans***.** To monitor the SopB delivered into fungal filaments from *S.* Typhimurium, filamentous *C. albicans* SSY50-B cells (i.e., the genetically engineered *Candida* strain with constitutive filaments under DOX) cultured in the presence of 20  $\mu$ g of DOX/ml were coinfected with wild type or the *S.* Typhimurium *sipB* mutant (TTSS translocation machinery component deficient) expressing FLAG epitope-tagged SopB (50) under 0.05% L-arabinose for 15 h. After gentamicin treatment (100  $\mu$ g/ml) for 1 h to kill exterior filamentbinding *Salmonella*, fungal cells were processed for immunofluorescence by using monoclonal anti-FLAG M2 FITC antibody (Sigma-Aldrich Corp., St. Louis, MO) based on the manufacturer's protocol. Fluorescent observation of SopB in filaments was performed by using confocal laser microscopy (TCS-NT; Leica Microsystems).

**qRT-PCR.** Quantitative reverse transcription-PCR (qRT-PCR) was performed using the CHROMO4 real-time PCR system (MJ Research, Inc., Waltham, MA). After disruption with glass beads (Sigma-Aldrich), total RNA was isolated according to the protocol of an RNeasy minikit (Qiagen, Valencia, CA), including an on-column DNase digestion with RNase-free DNase (Qiagen). After the RNA was isolated, 50 ng of total RNA was used for the qRT-PCR using a SuperScript III Platinum SYBR Green One-Step qRT-PCR kit (Invitrogen, Carlsbad, CA). Primers were designed by using Primer3Input Software (v0.4.0; http://frodo.wi.mit.edu/primer3/) and are listed in Table 2. Relative expression levels were calculated by using the  $2^{-\Delta\Delta CT}$  method (33). The control genes 18S rRNA and 16S rRNA were used to normalize the expression data for *Candida* and *Salmonella*, respectively. The annealing temperature was 60°C for all of the genes in the present study. To investigate the transcriptional regulations of *sopB* and *sipB* by *C. albicans* supernatants, overnight cultures of *C. albicans* DAY185 Δtup1 versus Δsuv3 (at 25°C) and *C. albicans* SC5314 versus Δcph1/ *efg1* (at 37°C) were inoculated in YPD and cultured for 48 and 24 h, respectively. Supernatants were quickly recovered, filtered, and stored at  $-80^{\circ}$ C before use. The *sopB* and *sipB* transcript levels were investigated after exposure to prepared supernatants from *C. albicans* or farnesol (Sigma-Aldrich; 100 and 200 M concentrations) for 2 h. In contrast, *C. albicans* DAY185 filamentous cells on silicone pads (18 h) were exposed to the *S.* Typhimurium wild type and mutants for 3 h. After infection by the *Salmonella* strains, the *C. albicans* filamentous cells on pads were washed twice with PBS and then quickly recovered by vigorous pipetting. The results were normalized using the *E. coli* strain HB101, which has no impact on *C. albicans* filamentation and biofilm formation.

**Statistical analysis.** *C. elegans* survival was examined by using the Kaplan-Meier method, and differences were determined by using the log-rank test (STATA6; STATA, College Station, TX). Differences in the number from each experiment were determined by using a Student *t* test. Each result is a representative experiment of at least two independent biological replicates. A *P* value of 0.05 in all replicate experiments was considered statistically significant.

TABLE 2. Oligonucleotides used for qRT-PCR

Organism and gene	Orientation <sup>a</sup>	Sequence $(5'-3')$
Salmonella sopB	F	<b>CTTATACAACGGAATGCAGATTCTC</b>
	R	AGTTATAGAGGTTATGCAGCGAGTG
sipB	F R	ATTACTGCTTGGCAAGTTAATGACC <b>TTTGATACTGGCTTCATAGAGATCC</b>
16S rRNA	F R	TGTAGCGGTGAAATGCGTAG CAAGGGCACAACCTCCAAG
Candida		
TEC1	F R	TGGTGCTTATTCACGTGTCC TTCTGAATTTCCCGGTTTTG
HWP1	F R	CTCCAGCTGGCTCAAGTGGT TGGCAGATGGTTGCATGAGT
ALS3	F $\mathbb{R}$	<b>ACTTCCACAGCTGCTTCCAC</b> TGCAGATGGAGCATTACCAC
CDC42	F R	AGGGTGAAAAATTGGCTAAGGA TGCAGCTACTATAGCCTCGTCA
18S rRNA	F R	GTGCCAGCAGCCGCGGTA TGGACCGGCCAGCCAAGC

*<sup>a</sup>* F, forward primer; R, reverse primer.

## **RESULTS**

**Role of SPI-1 effectors in the viability of** *C. albicans***.** In order to evaluate the hypothesis that TTSS is involved in the *S*. Typhimurium-*C. albicans* interaction, we selected 10 mutant strains that have a mutation involving different TTSS effectors. They can be categorized into three groups: (i) strains with a mutation involving the SPI-1 system effectors, including SopB (48), SopD  $(69)$ , and SopE2  $(4)$ ;  $(ii)$  strains with a mutation involving the SPI-2 system effectors, including SsaE (40), SseB (23), and SseJ (49); and (iii) strains with a mutation involving TTSS-related regulators such as AdrA (18), LuxS (66), PhoP (20), and SsrA (7). Of note is that there was no significant difference in the growth rates *in vitro* among these *S.* Typhimurium mutants (data not shown).

Using this collection of *S.* Typhimurium strains, we compared the viability of *C. albicans* exposed to the *S.* Typhimurium wild-type (WT) strain or isogenic mutants using *in vitro* coinfection conditions. At 25°C after 5 days, the deletion of *sopB* strongly enhanced the survival of *C. albicans* by 16.6-fold compared to the WT strain (Fig. 1). In contrast, deletion of SPI-2 gene *ssaE*, *sseB*, or *sseJ* or global regulator gene *adrA*, *luxS*, *phoP*, or *ssrA* still repressed the fungal viability similar to the WT. Previous reports demonstrated that translocases (including SipB) controlled by SPI-1 are required for translocation of SopB into the host cell cytosol (71). To explore whether the SipB translocation machinery component is also linked to killing of *C. albicans*, we examined the viability of *C. albicans* coinfected with the *sipB* mutant. Consistent with the results observed with the *sopB* mutant, the viability of *C. albicans* was also increased as a result of the *sipB* deletion (16.8-fold; Fig. 1). To summarize the analysis of the *S.* Typhimurium mutant strains, the *sopB* effector and the *sipB* translocase influence the anticandidal activity of the bacterium.



FIG. 1. The *S.* Typhimurium *sopB* effector influences the viability of *C. albicans* under an *in vitro* planktonic environment. The viability of *C. albicans* in the presence of *S.* Typhimurium wild type (WT) or various mutants was determined at 25°C after 5 days. The error bars represent the standard errors of the mean for two independent biological replicates. Asterisks indicate significantly different values (*P* 0.05; Student *t* test).

**The** *sopB* **effector selectively represses the viability of** *C. albicans***.** Gram-negative bacteria, such as *A. baumannii* (52) and *P. aeruginosa* (25) bind to and kill *C. albicans* filaments without affecting yeast cells, and our group showed that *S.* Typhimurium may preferentially kill filamentous *C. albicans* cells over yeast cells (67). However, the viability measured using CFU assays does not accurately reflect the number of viable cells for filamentous fungi (9). Therefore, in order to evaluate the effect of the *sopB* effector against *C. albicans* filaments, we also used XTT assays (38). As expected, *C. albicans*  $\Delta t \psi l$  cells grown under conditions that promote filament development were highly susceptible to *S.* Typhimurium WT, whereas deleting *sopB* and *sipB* limited the effect of *S.* Typhimurium (Fig. 2A). Consistently, we verified a similar activity using the *C. albicans* SSY50-B filaments (Fig. 2B). Importantly, the effect was limited in yeast-type cells from *C. albicans*  $\Delta suv3$ or from strain SSY50-B grown without DOX (Fig. 2). These results indicate that the *sopB* effector is important for the killing of *C. albicans* filaments.

**SopB is translocated into filaments of** *C. albicans* **through SipB.** To visualize the translocation of SopB into filaments, *C. albicans* cells were coinfected with *S.* Typhimurium strains expressing FLAG-tagged SopB that enable immunodetection of the protein (Table 1). We found that the fluorescent SopB protein shifts into the interior of the *C. albicans* filaments; however, there was no signal or SopB translocation when we used the *sipB* mutant (merged images in Fig. 3). In addition, we detected weak fluorescent SopB signals in yeast-type cells (data not shown). This finding demonstrates that, similar to what happens during the interaction of mammalian cells with *S.* Typhimurium (50), the SopB effector protein translocates into fungal filaments via SipB.

*sopB* **is essential for the attachment to** *C. albicans* **filaments.** We hypothesize that the *sopB* effector can also influence *S.* Typhimurium attachment to *C. albicans* filaments, since SPI-1 effectors have been shown to be required for *Salmonella* attachment to eukaryotic host cells (31). To evaluate this hypothesis, we investigated the attachment of *S.* Typhimurium WT and the *sopB* mutant to filaments produced by *C. albicans*. In



FIG. 2. *S.* Typhimurium kills *C. albicans* filaments via the *sopB* effector. Viability of *C. albicans* filaments using the XTT assay. (A) *C. albicans*  $\Delta t$ *up1* or  $\Delta s$ *uv3* strains were cultured at 25°C for 48 h for constitutive filament production or normal yeast cells, respectively. (B) In addition, the experiments with *C. albicans* SSY50-B were performed in the presence or absence of DOX (20  $\mu$ g/ml) for abundant filaments or yeast form cells. Filaments or yeast cells were exposed to *S.* Typhimurium wild-type (WT) and mutant strains for 24 h. The cell viability was evaluated and normalized against the HB101 control. Bars represent the standard errors of the mean for two independent biological replicates.

this experiment, *C. albicans* SSY50-B filaments were prepared in the presence of 20  $\mu$ g of DOX/ml and then added to either the GFP-expressing *S.* Typhimurium WT or the *sopB* mutant. As expected, fluorescent GFP intensity was decreased in the *sopB* deletion mutant on *C. albicans* filaments compared to the WT (Fig. 4A). Moreover, by direct CFU counting, we verified that the deletion of either *sopB* or *sipB* resulted in a significant reduction in bacterial attachment to *C. albicans* filaments consistently by  $>10$ -fold, and this repression was abolished by complementation of SopB (Fig.  $4A$ ;  $P < 0.05$ ). These results suggest that, at least in part, the *sopB* effector share the function for attachment on fungal filaments with mammalian cells.

**The** *sopB* **effector mediates inhibition of** *C. albicans* **filaments** *in vivo***.** To explore whether *sopB* plays a direct role in the inhibition of *C. albicans* filaments *in vivo*, we utilized the *C. elegans* coinfection assay. Using this assay we previously reported that *S.* Typhimurium (but not nonpathogenic *E. coli* strains) can inhibit *C. albicans* filamentation (67), even though *S.* Typhimurium alone is toxic in *C. elegans* (data not shown). Corroborating the viability tests, deleting *sopB* and *sipB* significantly increased the number of filament-coated worms compared to the WT (Fig. 4B), but filamentation in the presence of the *sopB* mutant was less than that observed for *E. coli* HB101 or *C. albicans* alone ( $P < 0.05$ ). Corroborating these results, we



FIG. 3. Translocation of SopB into *C. albicans* filaments via SipB. SopB translocation in *S.* Typhimurium wild-type (top row) and *sipB* mutant (bottom row) was visualized by confocal microscopy. Scale bars, 4.2 m. The inset shows an enlarged view of the area indicated by the arrow. An immunofluorescence assay was performed as described in Materials and Methods.

found that the number of worms with filaments was restored by complementing SopB. This finding using the model host *C. elegans* indicates that the *sopB* effector is an important factor that inhibits *C. albicans* filaments *in vivo*.

We also evaluated whether the *sopB* effector is involved in the inhibition of preformed filaments. After the forming filaments of *C. albicans* in nematodes for 1 day, we transferred *C. elegans* into fresh liquid medium containing the GFP expressing *S.* Typhimurium WT and the *sopB* mutant (Table 1). Consistently, we found that exposure to *S.* Typhimurium WT inhibits filament elongation, but the effect of the *sopB* mutant was significantly less (Fig. 4C). In addition, we introduced GFP-expressing *Salmonella* strains to visualize the binding of *S.* Typhimurium to *C. albicans* filaments and inhibit their elongation (Fig. 4C, white arrow). We found that, similar to our *in vitro* studies reported above, *sopB* is essential for the association of *S.* Typhimurium with *C. albicans* filaments. Moreover, as in the *in vitro* and *in vivo* studies detailed above, our findings also indicated that *sopB* is essential for the initiation of the fungal germ tubes (Fig. 4D). Hence, we conclude that the *sopB* effector is directly involved in an antagonistic effect against *C. albicans* filaments at different stages of hyphal development.

**The** *sopB* **effector mediates the** *S.* **Typhimurium effect on** *C. albicans* **biofilm.** The morphological transition from yeast to filaments is a major requirement for biofilm formation, as well as virulence (16, 55). Therefore, we considered the possibility that the *sopB* effector may influence *C. albicans* biofilm formation. This hypothesis is an extension of our finding above in which *S.* Typhimurium attaches to filaments (Fig. 4A), and this inhibited filament formation and elongation (Fig. 4B and C) and selectively killed *C. albicans* filaments (Fig. 1 and 2) via the *sopB* effector. We evaluated the effect of *S.* Typhimurium on the *C. albicans* biofilm using silicone pads (67). As shown in Fig. 4E, the robust *C. albicans* biofilm was dramatically repressed by the *S.* Typhimurium WT. This profound reduction was depleted when the *C. albicans* biofilm was exposed to the  $\sin B$  or  $\sin B$  mutants ( $P < 0.05$  compared to the WT), while

they were still statistically different with the biofilms of *C. albicans* alone. Accordingly, complementing SopB restored the inhibition of biofilm formation. Our observations confirm that the killing of filaments medicated by *sopB* effector affects filamentation, as well as fungal biofilm formation.

**The** *S.* **Typhimurium** *sopB* **effector negatively regulates the transcription of** *TEC1***,** *HWP1***,** *ALS3***, and** *CDC42* **in** *C. albicans.* Using qRT-PCR, we found that *sopB* is upregulated by supernatant obtained from *C. albicans* filaments [Fig. 5A;  $(2.5 \pm$ 0.4)-fold in  $\Delta tup1$  versus  $\Delta suv3$  strains and (8.9  $\pm$  0.3)-fold in SC5314 versus  $\Delta cph1/\Delta e$ fg1 strains]. Also, under these conditions, *sipB* was slightly induced by the supernatant from filamentous *C. albicans* cells. At least in part, these findings are in agreement with our results on the role of *sopB* and *sipB* in competing *C. albicans* filaments (Fig. 1). We further evaluated whether the *C. albicans* quorum-sensing signal farnesol influenced the regulation of *sopB* and *sipB*, but farnesol at 100 and  $200 \mu M$  did not alter the transcription of either of these genes (data not shown).

Initially, we hypothesized that *S.* Typhimurium TTSS effectors, including SopB and SipB, regulate specific components associated with the *C. albicans* morphological transition. Preliminary results among essential virulence factors, including *NRG1* (which encodes a transcriptional repressor and regulates filament formation and virulence) (44), *TUP1* (which encodes a transcriptional corepressor and represses filamentous growth) (10), *TEC1* (which encodes a TEA/ATTS transcription factor involved in the pheromone response pathway in white cells and the regulation of filament-specific genes) (60), *EFG1* (which encodes a transcriptional repressor) (64), *HWP1* (which encodes a filament-specific cell wall protein) (47), *ALS3* (which encodes a filament-specific adhesion) (72), *SOD2* (which encodes superoxide dismutase) (27), and *CDC42* (which encodes a Rho-type GTPase) (56), indicate that *S.* Typhimurium supernatants selectively repressed transcriptional levels of *TEC1*, *HWP1*, *ALS3*, and *CDC42* (data not shown). Moreover, we investigated whether the transcription



FIG. 4. *S.* Typhimurium strongly inhibits *C. albicans* filamentation and biofilm formation via the *sopB* effector. (A) Attachment of *S.* Typhimurium wild-type (WT) and *sopB* mutant strains to the *C. albicans* filaments. *C. albicans* SSY50-B filaments were formed in 96-well plates with 20 µg of DOX/ml and infected with GFP-expressing *Salmonella* strains for 15 h at 37°C. *Salmonella* attachment on *C. albicans* filaments was visualized by using fluorescence microscopy (scale bars, 1 mm) and counted by using the CFU assay. (B) Inhibition of *C. albicans* DAY185 filamentation in the *C. elegans* coinfection model. (C) Repression of filament elongation in the *C. elegans* coinfection model. An arrow indicates the GFP expression of *S.* Typhimurium cells on the *C. albicans* filaments (scale bars, 1 mm). (D) Inhibition of germ tube formation. (E) *C. albicans* biofilm formation on silicone squares in spider medium for 60 h at 37°C (NT, no treatment; CA, *C. albicans* alone; CAWT, *C. albicans* cocultured with *S.* Typhimurium wild type; CA+sopB or sipB, C. albicans cocultured with the *S.* Typhimurium sopB or sipB mutants; CA+sopB/SopB, C. *albicans* cocultured with the *S.* Typhimurium *sopB* mutant overproducing SopB).

of *TEC1*, *HWP1*, *ALS3*, and *CDC42* genes in *C. albicans* are influenced by the direct contact between the fungus and *S.* Typhimurium and the translocation of the *sopB* effector. The qRT-PCR assay showed that the transcriptional levels of *TEC1*  $[(-5.9 \pm 0.3)$ -fold], *HWP1*  $[(-7.1 \pm 1.6)$ -fold], and *ALS3*  $[(-5.6 \pm 0.3)$ -fold], were significantly repressed by *S*. Typhimurium WT, whereas these reductions were restored by the deletion of *sopB* effector or the *sipB* translocase gene

(Fig. 5B). It is reasonable that the function of *TEC1*, *HWP1*, and *ALS3* is linked to hyphal development and biofilm formation in *C. albicans* as described previously (47, 60, 72). More importantly, the transcription of *CDC42* was strongly decreased by  $(10.4 \pm 0.6)$ -fold in the presence of *S*. Typhimurium. Critically, *CDC42* is essential for *Candida* viability (39). Therefore, our qRT-PCR results suggest that, at least in part, the *sopB* effector translocated into filaments through



FIG. 5. Gene expression in *S.* Typhimurium and *C. albicans*. (A) Transcription of *sopB* and *sipB* of the *S.* Typhimurium wild type in the presence of supernatants from filaments or yeast-form *C. albicans*. (B) Transcriptional levels of *TEC1*, *HWP1*, *ALS3*, and *CDC42* in the presence or absence of *sopB* or *sipB*. The fold change was normalized by comparison to an HB101 control.

SipB may kill *C. albicans* filaments through associating with *CDC42*.

# **DISCUSSION**

Bacterial-fungal encounters are common in nature, as well as in clinical settings, and shape microbial pathogenesis. The interactions between fungal and bacterial pathogens have been previously extensively investigated (2, 5, 8, 25, 52, 67). Of importance is the diverse population of bacteria and fungi that coexist within the human intestinal tract. However, very little is known about the specific mechanisms underlying these interactions. In the present study we demonstrate that TTSS and especially the *sopB* effector are essential for *S.* Typhimurium to survive the interaction with intestinal fungi, such as *C. albicans*. The role of the *sopB* effector, as well as that of the associated translocase SipB, is based on the following five findings. (i) The deletion of *sopB* significantly increased the survival of *C. albicans in vitro* (Fig. 1). (ii) The *sopB* effector translocates into filaments via SipB (Fig. 3) and kills *C. albicans* filaments (Fig. 2). (iii) Similar to the findings *in vitro*, *sopB* of *S.* Typhimurium diminished the viability of *C. albicans* filaments during *C. elegans* infection (Fig. 4). (iv) The *sopB* effector repressed the elongation of filaments and germ tubes, as well as *Candida* biofilm formation (Fig. 4). (v) Remarkably, the *sopB* effector is associated with the transcriptional repression of *CDC42* in *C. albicans* (Fig. 5). Based on these findings, we report that the *sopB* effector of *S.* Typhimurium is an important weapon for

competing against fungi, and this constitutes a novel role for bacterial TTSS effectors.

We recently utilized *C. elegans* to study monomicrobial infection due to *C. albicans* (11, 53) or *S.* Typhimurium (1), as well as to study the *C. albicans*-*S.* Typhimurium coinfection (67). This model of intestinal infection is particularly relevant for the study of microbial infections (45). In our previous observation (67), the *S.* Typhimurium-*C. albicans* competition in polymicrobial infection seemed to be mediated by direct adhesion to filaments, as well as growth-dependent molecules secreted by the bacteria. Therefore, we investigated the hypothesis that TTSS effectors may play a role in *S.* Typhimurium competition against *C. albicans*. The TTSS apparatus and its effector proteins are exclusively expressed and secreted at the stationary phase of growth (61) and are strongly linked to virulence traits, such as contact, invasion, and biofilm formation (37). Interestingly, we found that the antagonistic interaction between *S.* Typhimurium and *C. albicans* is multifactorial and that the viability of *C. albicans* is associated with the *S.* Typhimurium *sopB* and *sipB* TTSS translocation machinery units (Fig. 1).

We show that the TTSS genes regulated by SPI-1 (including *sopB* and *sipB*) are involved in competing with fungal pathogens. TTSS that are regulated by SPI-1 mainly mediate the initial attachment of *S.* Typhimurium on mammalian cells and the initiation of mammalian cell death is SPI-1 dependent (30), whereas the SPI-2 component of TTSS involve postinvasion processing, including vacuole maturation (15). Importantly, *sopB* and *sipB* are associated with SPI-1 regulation. The *Salmonella* SopB (also known as SigD) is a homologue of IpgD from *Shigella flexneri* (46) and is an inositol phosphate that acts on the phospholipids in the host cell membrane (30, 57). SopB is the SPI-1-regulated effector for TTSS that is quickly translocated into the mammalian host after contact (50) and is linked to enteropathogenesis of mammalian cells since *sopB* defective mutants of *Salmonella* are attenuated (48). Therefore, we suggest that SopB may modify membrane phospholipids of *C. albicans* filaments and that this modification results in filament death. In addition, SipB is required for the assembly of the TTSS needle complex and is one of the effectors regulated by SPI-1. Interestingly, SipB helps the translocation of SPI-1 effectors, including SopB into host cells (71, 74), and triggers mammalian cell death directly (24). Of note is that the regulatory system encoded by *ssrA*, which controls the SPI-2 system (7), had no effect in the competition with *C. albicans* (Fig. 1). Consistent with these observations, the *sopB* effector is essential for the *S.* Typhimurium attachment to filaments of *C. albicans* (Fig. 4A). Furthermore, after translocating into the filaments via the SipB translocase (Fig. 3), the *sopB* effector can inhibit filament elongation (Fig. 4C) in *C. elegans*, as well as fungal biofilm formation on silicone squares (Fig. 4E).

Generally, bacteria, including *S.* Typhimurium, produce quorum-sensing (QS) signaling molecules to regulate expression of a number of genes, including the *luxS* gene, which is important for the synthesis of this QS signal in *S.* Typhimurium (66). Importantly, the QS signaling molecule is also resistant to acid and heat (65). Boone et al. (8) identified a novel signaling molecule in *B. cenocepacia* that is a structural homologue of a QS molecule that inhibited germ tube and filament formation of *C. albicans*. Thus, we postulated that a QS-related gene is also essential in interacting with fungi. Unexpectedly, in the present study, the deletion of *luxS* had no impact on the viability of *C. albicans* (Fig. 1), which was also true with another other QS sensor gene *sdiA* that did not inhibit *C. albicans* filaments (65). Of note is that the activity of this signal molecule is maximal at mid-exponential phase and dramatically decreases at the stationary phase (65). Although bacterial QS signals were not responsible for the antifungal effects of *S.* Typhimurium on *C. albicans* directly, previous work has shown that  $3$ -oxo-C<sub>12</sub> homoserine lactone, the QS signaling molecule produced by *P. aeruginosa*, was involved in *C. albicans* filamentation (26), and our group has reported that QS is involved in the *Acinetobacter*-*Candida* interaction (52). These results suggest that different strategies to fight *C. albicans* may be dependent on the specific genus of bacteria.

Even though TTSS-related components were not directly linked in the *Pseudomonas*-*Candida* interaction, previous reports demonstrate that effector proteins such as ExoS are toxic in *Saccharomyces cerevisiae* (63) and clearly contribute to the toxicity of *Pseudomonas* toward amoebae (36). Importantly, it has been reported that SopB strongly influences the viability of *S. cerevisiae* (3). Interestingly, ExoS and SopB share a function in mammals by modulating GTPase and actin polymerization (3, 36). Importantly, we show that the *sopB* effector strongly repressed *CDC42* mRNA levels (Fig. 5B). Notably, silencing of *CDC42* is lethal in *Candida* (39) and inhibits the growth of mammalian cells (70). More importantly, Cdc42p (cell division cycle 42) is involved in *C. albicans* filament-specific characteristics, including hyphal growth and filament-specific gene transcripts (12, 68, 73). A recent report describes that the SopB effector protein strongly binds with the small G-protein Cdc42p in yeast (56), as well as in mammalian cells (57). Therefore, it seems reasonable to assume that, at lease in part, the SopB effector of *S.* Typhimurium affects *C. albicans* filaments through association with Cdc42p. In addition, because, Cdc42p is also required for invasion via hyphal growth of *C. albicans* (6), our future goal is to establish the pathway that inhibits or kills filaments through the SopB effector-Cdc42p association.

We also report the observation that the *C. albicans* supernatant induces *sopB* transcripts, whereas the *sopB* effector repressed *TEC1*, *HWP1*, and *ALS3* transcripts (Fig. 5). It was extensively established that filamentation and biofilm formation are involved in *C. albicans* virulence and that *TEC1*, *HWP1*, and *ALS3* are important key genes for the hyphal development and biofilm formation of *C. albicans* (47, 60, 72). Equally important, other investigators confirmed that deletion of *TEC1* and *HWP1* resulted in a significant reduction of *C. albicans* virulence in *Galleria mellonella* (16) and mice (62). Moreover, our qRT-PCR results are consistent with our biofilm data that the *C. albicans* biofilm was critically repressed by the *sopB* effector (Fig. 4E). Therefore, these results indicate that in addition to its effect in mammals, SopB may influence the transcriptions of genes involved in hypha- and biofilmassociated fungal pathogenesis during killing events.

Bacterial-fungal interactions play a significant role in human health since they may enhance, modulate, or decrease microbial pathogenesis (42). Intestinal bacteria need to overcome the other intestinal microflora, and the interaction of *C. albicans* with intestinal Gram-negative bacteria may control filamentation. The *sopB* effector plays a critical role in allowing the bacteria to attach and kill *C. albicans* filaments, and the viability and filamentation of *C. albicans* is influenced by *sopB*. Our working model suggests that in the presence of *C. albicans* filaments, the *sopB* effector is activated. The SopB effector translocates into the fungal filaments via SipB translocase and clearly kills filaments. This killing event may trigger the repression of biofilm formation. Our results propose a novel role for TTSS effectors in bacterial-fungal interactions.

## **ACKNOWLEDGMENTS**

This study was supported by grants from the National Institutes of Health (P01 AI083214, R01 AI075286, and R21 AI079569) to E.M.

We are grateful for the pSB2908 and pCM18 plasmids provided by Jorge E. Galán (Yale University) and Thomas K. Wood (Texas A&M University), respectively. We thank Michael McClelland (Sidney Kimmel Cancer Center) for providing the *S.* Typhimurium 14028 wild-type and the isogenic mutants. We also thank Beth B. Fuchs for help with the confocal microscopy and Jeffrey J. Coleman for useful discussions.

### **REFERENCES**

- 1. **Aballay, A., and F. M. Ausubel.** 2001. Programmed cell death mediated by *ced-3* and *ced-4* protects *Caenorhabditis elegans* from *Salmonella typhimurium*-mediated killing. Proc. Natl. Acad. Sci. U. S. A. **98:**2735–2739.
- 2. **Adam, B., G. S. Baillie, and L. J. Douglas.** 2002. Mixed species biofilms of *Candida albicans* and *Staphylococcus epidermidis*. J. Med. Microbiol. **51:**344– 349.
- 3. **Alema´n, A., et al.** 2005. The amino-terminal non-catalytic region of *Salmonella typhimurium* SigD affects actin organization in yeast and mammalian cells. Cell Microbiol. **7:**1432–1436.
- 4. **Bakshi, C. S., et al.** 2000. Identification of SopE2, a *Salmonella* secreted protein which is highly homologous to SopE and involved in bacterial invasion of epithelial cells. J. Bacteriol. **182:**2341–2344.
- 5. **Bamford, C. V., et al.** 2009. *Streptococcus gordonii* modulates *Candida albicans* biofilm formation through intergeneric communication. Infect. Immun. **77:**3696–3704.
- 6. **Bassilana, M., J. Hopkins, and R. A. Arkowitz.** 2005. Regulation of the Cdc42/Cdc24 GTPase module during *Candida albicans* hyphal growth. Eukaryot. Cell **4:**588–603.
- 7. **Bohez, L., et al.** 2008. The *Salmonella* pathogenicity island 2 regulator *ssrA* promotes reproductive tract but not intestinal colonization in chickens. Vet. Microbiol. **126:**216–224.
- 8. **Boone, C., et al.** 2008. A novel DSF-like signal from *Burkholderia cenocepacia* interferes with *Candida albicans* morphological transition. ISME J. **2:**27–36.
- 9. **Bowman, J. C., et al.** 2001. Quantitative PCR assay to measure *Aspergillus fumigatus* burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. **45:**3474–3481.
- 10. **Braun, B. R., and A. D. Johnson.** 1997. Control of filament formation in *Candida albicans* by the transcriptional repressor *TUP1*. Science **277:**105– 109.
- 11. **Breger, J., et al.** 2007. Antifungal chemical compounds identified using a *Caenorhabditis elegans* pathogenicity assay. PLoS Pathog. **3:**e18.
- 12. **Court, H., and P. Sudbery.** 2007. Regulation of Cdc42 GTPase activity in the formation of hyphae in *Candida albicans*. Mol. Biol. Cell **18:**265–281.
- 13. **Davis, D., R. B. Wilson, and A. P. Mitchell.** 2000. *RIM101*-dependent andindependent pathways govern pH responses in *Candida albicans*. Mol. Cell. Biol. **20:**971–978.
- 14. **Donegan, K., C. Matyac, R. Seidler, and A. Porteous.** 1991. Evaluation of methods for sampling, recovery, and enumeration of bacteria applied to the phylloplane. Appl. Environ. Microbiol. **57:**51–56.
- 15. **Drecktrah, D., L. A. Knodler, K. Galbraith, and O. Steele-Mortimer.** 2005. The *Salmonella* SPI1 effector SopB stimulates nitric oxide production long after invasion. Cell Microbiol. **7:**105–113.
- 16. **Fuchs, B. B., et al.** 2010. Role of filamentation in *Galleria mellonella* killing by *Candida albicans*. Microbes Infect. **12:**488–496.
- 17. **Gala´n, J. E., and H. Wolf-Watz.** 2006. Protein delivery into eukaryotic cells by type III secretion machines. Nature **444:**567–573.
- 18. **García, B., et al.** 2004. Role of the GGDEF protein family in *Salmonella* cellulose biosynthesis and biofilm formation. Mol. Microbiol. **54:**264–277.
- 19. **Gillum, A. M., E. Y. Tsay, and D. R. Kirsch.** 1984. Isolation of the *Candida albicans* gene for orotidine-5-phosphate decarboxylase by complementation of *Saccharomyces cerevisiae ura3* and *Escherichia coli pyrF* mutations. Mol. Gen. Genet. **198:**179–182.
- 20. **Groisman, E. A., E. Chiao, C. J. Lipps, and F. Heffron.** 1989. *Salmonella*

*typhimurium phoP* virulence gene is a transcriptional regulator. Proc. Natl. Acad. Sci. U. S. A. **86:**7077–7081.

- 21. **Hansen, M. C., R. J. J. Palmer, C. Udsen, D. C. White, and S. Molin.** 2001. Assessment of GFP fluorescence in cells of *Streptococcus gordonii* under conditions of low pH and low oxygen concentration. Microbiology **147:**1383– 1391.
- 22. **Harriott, M. M., and M. C. Noverr.** 2010. Ability of *Candida albicans* mutants to induce *Staphylococcus aureus* vancomycin resistance during polymicrobial biofilm formation. Antimicrob. Agents Chemother. **54:**3746–3755.
- 23. **Hensel, M., et al.** 1998. Genes encoding putative effector proteins of the type III secretion system of *Salmonella* pathogenicity island 2 are required for bacterial virulence and proliferation in macrophages. Mol. Microbiol. **30:** 163–174.
- 24. **Hersh, D., et al.** 1999. The *Salmonella* invasin SipB induces macrophage apoptosis by binding to caspase-1. Proc. Natl. Acad. Sci. U. S. A. **96:**2396– 2401.
- 25. **Hogan, D. A., and R. Kolter.** 2002. *Pseudomonas*-*Candida* interactions: an ecological role for virulence factors. Science **296:**2229–2232.
- 26. **Hogan, D. A., A. Vik, and R. Kolter.** 2004. A *Pseudomonas aeruginosa* quorum-sensing molecule influences *Candida albicans* morphology. Mol. Microbiol. **54:**1212–1223.
- 27. **Hwang, C. S., Y. U. Baek, H. S. Yim, and S. O. Kang.** 2003. Protective roles of mitochondrial manganese-containing superoxide dismutase against various stresses in *Candida albicans*. Yeast **20:**929–941.
- 28. **Keeney, K. M., and B. B. Finlay.** 2011. Enteric pathogen exploitation of the microbiota-generated nutrient environment of the gut. Curr. Opin. Microbiol. **14:**92–98.
- 29. **Kim, D. H., et al.** 2002. A conserved p38 MAP kinase pathway in *Caenorhabditis elegans* innate immunity. Science **297:**623–626.
- 30. **Knodler, L. A., B. B. Finlay, and O. Steele-Mortimer.** 2005. The *Salmonella* effector protein SopB protects epithelial cells from apoptosis by sustained activation of Akt. J. Biol. Chem. **280:**9058–9064.
- 31. **Lara-Tejero, M., and J. E. Gala´n.** 2009. *Salmonella enterica* serovar typhimurium pathogenicity island 1-encoded type III secretion system translocases mediate intimate attachment to nonphagocytic cells. Infect. Immun. **77:**2635–2642.
- 32. Liu, H., J. Köhler, and G. R. Fink. 1994. Suppression of hyphal formation in *Candida albicans* by mutation of a STE12 homolog. Science **266:**1723–1726.
- 33. **Livak, K. J., and T. D. Schmittgen.** 2001. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. Methods **25:**402–408.
- 34. **Lo, H. J., et al.** 1997. Nonfilamentous *C. albicans* mutants are avirulent. Cell **90:**939–949.
- 35. **Ly, K. T., and J. E. Casanova.** 2007. Mechanisms of *Salmonella* entry into host cell. Cell Microbiol. **9:**2103–2111.
- 36. **Matz, C., et al.** 2008. *Pseudomonas aeruginosa* uses type III secretion system to kill biofilm-associated amoebae. ISME J. **2:**843–852.
- 37. **McGhie, E. J., L. C. Brawn, P. J. Hume, D. Humphreys, and V. Koronakis.** 2009. *Salmonella* takes control: effector-driven manipulation of the host. Curr. Opin. Microbiol. **12:**117–124.
- 38. **Meshulam, T., S. M. Levitz, L. Christin, and R. D. Diamond.** 1995. A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-*bis*-(2-methoxy-4-nitro-5-sulphenyl)-(2*H*)-tetrazolium-5-carboxanilide (XTT). J. Infect. Dis. **172:**1153–1156.
- 39. **Michel, S., et al.** 2002. Generation of conditional lethal *Candida albicans* mutants by inducible deletion of essential genes. Mol. Microbiol. **46:**269–280.
- 40. **Miki, T., Y. Shibagaki, H. Danbara, and N. Okada.** 2009. Functional characterization of SsaE, a novel chaperone protein of the type III secretion system encoded by *Salmonella* pathogenicity island 2. J. Bacteriol. **191:**6843– 6854.
- 41. **Miyata, S., J. Begun, E. R. Troemel, and F. M. Ausubel.** 2008. DAF-16 dependent suppression of immunity during reproduction in *Caenorhabditis elegans*. Genetics **178:**903–918.
- 42. **Morales, D. K., and D. A. Hogan.** 2010. *Candida albicans* interactions with bacteria in the context of human health and disease. PLoS Pathog. **6:**e1000886.
- 43. **Moy, T. I., et al.** 2006. Identification of novel antimicrobials using a liveanimal infection model. Proc. Natl. Acad. Sci. U. S. A. **103:**10414–10419.
- 44. **Murad, A. M., et al.** 2001. NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in *Candida albicans*. EMBO J. **20:**4742–4752.
- 45. **Mylonakis, E., A. Casadevall, and F. M. Ausubel.** 2007. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog. **3:**e101.
- 46. **Niebuhr, K., et al.** 2000. IpgD, a protein secreted by the type III secretion machinery of *Shigella flexneri*, is chaperoned by IpgE and implicated in entry focus formation. Mol. Microbiol. **38:**8–19.
- 47. **Nobile, C. J., J. E. Nett, D. R. Andes, and A. P. Mitchell.** 2006. Function of *Candida albicans* adhesin Hwp1 in biofilm formation. Eukaryot. Cell **5:**1604– 1610.
- 48. **Norris, F. A., M. P. Wilson, T. S. Wallis, E. E. Galyov, and P. W. Majerus.** 1998. SopB, a protein required for virulence of *Salmonella dublin*, is an inositol phosphate phosphatase. Proc. Natl. Acad. Sci. U. S. A. **95:**14057– 14059.
- 49. **Ohlson, M. B., K. Fluhr, C. L. Birmingham, J. H. Brumell, and S. I. Miller.** 2005. SseJ deacylase activity by *Salmonella enterica* serovar Typhimurium promotes virulence in mice. Infect. Immun. **73:**6249–6259.
- 50. **Patel, J. C., K. Hueffer, T. T. Lam, and J. E. Gala´n.** 2009. Diversification of a *Salmonella* virulence protein function by ubiquitin-dependent differential localization. Cell **137:**283–294.
- 51. **Peleg, A. Y., D. A. Hogan, and E. Mylonakis.** 2010. Medically important bacterial-fungal interactions. Nat. Rev. Microbiol. **8:**340–349.
- 52. **Peleg, A. Y., et al.** 2008. Prokaryote-eukaryote interactions identified by using *Caenorhabditis elegans*. Proc. Natl. Acad. Sci. U. S. A. **105:**14585–14590.
- 53. **Pukkila-Worley, R., A. Y. Peleg, E. Tampakakis, and E. Mylonakis.** 2009. *Candida albicans* hyphal formation and virulence assessed using a *Caenorhabditis elegans* infection model. Eukaryot. Cell **8:**1750–1758.
- 54. **Qin, J., et al.** 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature **464:**59–65.
- 55. **Richard, M. L., C. J. Nobile, V. M. Bruno, and A. P. Mitchell.** 2005. *Candida albicans* biofilm-defective mutants. Eukaryot. Cell **4:**1493–1502.
- 56. **Rodrı´guez-Escudero, I., R. Rotger, V. J. Cid, and M. Molina.** 2006. Inhibition of Cdc42-dependent signaling in *Saccharomyces cerevisiae* by phosphatasedead SigD/SopB from *Salmonella typhimurium*. Microbiology **152:**3437– 3452.
- 57. **Rogers, L. D., et al.** 2008. Identification of cognate host targets and specific ubiquitylation sites on the *Salmonella* SPI-1 effector SopB/SigD. J. Proteomics **71:**97–108.
- 58. **Santiviago, C. A., et al.** 2009. Analysis of pools of targeted *Salmonella* deletion mutants identifies novel genes affecting fitness during competitive infection in mice. PLoS Pathog. **5:**e1000477.
- 59. **Saville, S. P., A. L. Lazzell, C. Monteagudo, and J. L. Lopez-Ribot.** 2003. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of *Candida albicans* during infection. Eukaryot. Cell **2:**1053–1060.
- 60. Schweizer, A., S. Rupp, B. N. Taylor, M. Röllinghoff, and K. Schröppel. 2000. The TEA/ATTS transcription factor CaTec1p regulates hyphal development and virulence in *Candida albicans*. Mol. Microbiol. **38:**435–445.
- 61. **Song, M., et al.** 2004. ppGpp-dependent stationary phase induction of genes on *Salmonella* pathogenicity island 1. J. Biol. Chem. **279:**34183–34190.
- 62. **Staab, J. F., S. D. Bradway, P. L. Fidel, and P. Sundstrom.** 1996. Adhesive and mammalian transglutaminase substrate properties of *Candida albicans* Hwp1. Science **283:**1535–1538.
- 63. **Stirling, F. R., and T. J. Evans.** 2006. Effects of the type III secreted pseudomonal toxin ExoS in the yeast *Saccharomyces cerevisiae*. Microbiology **152:**2273–2285.
- 64. **Stoldt, V. R., A. Sonneborn, C. E. Leuker, and J. F. Ernst.** 1997. Efg1p, an essential regulator of morphogenesis of the human pathogen *Candida albicans*, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi. EMBO J. **16:**1982–1991.
- 65. **Surette, M. G., and B. L. Bassler.** 1998. Quorum sensing in *Escherichia coli* and *Salmonella typhimurium*. Proc. Natl. Acad. Sci. U. S. A. **95:**7046–7050.
- 66. **Surette, M. G., M. B. Miller, and B. L. Bassler.** 1999. Quorum sensing in *Escherichia coli*, *Salmonella typhimurium*, and *Vibrio harveyi*: a new family of genes responsible for autoinducer production. Proc. Natl. Acad. Sci. U. S. A. **96:**1639–1644.
- 67. **Tampakakis, E., A. Y. Peleg, and E. Mylonakis.** 2009. Interaction of *Candida albicans* with an intestinal pathogen, *Salmonella enterica* serovar Typhimurium. Eukaryot. Cell **8:**732–737.
- 68. **VandenBerg, A. L., A. S. Ibrahim, J. E. J. Edwards, K. A. Toenjes, and D. Johnson.** 2004. Cdc42p GTPase regulates the budded-to-hyphal-form transition and expression of hypha-specific transcripts in *Candida albicans*. Eukaryot. Cell **3:**724–734.
- 69. **Wood, M. W., et al.** 2004. Structural analysis of *Salmonella enterica* effector protein SopD. Biochim. Biophys. Acta **1698:**219–226.
- Wu, F., et al. 2008. RNA-interference-mediated Cdc42 silencing downregulates phosphorylation of STAT3 and suppresses growth in human bladdercancer cells. Biotechnol. Appl. Biochem. **49:**121–128.
- 71. **Zhang, S., et al.** 2002. The *Salmonella enterica* serotype typhimurium effector proteins SipA, SopA, SopB, SopD, and SopE2 act in concert to induce diarrhea in calves. Infect. Immun. **70:**3843–3855.
- 72. **Zhao, X., et al.** 2006. *Candida albicans* Als3p is required for wild-type biofilm formation on silicone elastomer surfaces. Microbiology **152:**2287–2299.
- 73. **Zheng, X. D., R. T. Lee, Y. M. Wang, Q. S. Lin, and Y. Wang.** 2007. Phosphorylation of Rga2, a Cdc42 GAP, by CDK/Hgc1 is crucial for *Candida albicans* hyphal growth. EMBO J. **26:**3760–3769.
- 74. **Zhou, D., and J. Gala´n** 2001. *Salmonella* entry into host cells: the work in concert of type III secreted effector proteins. Microbes Infect. **3:**1293–1298.